NCT00244400已完成不适用
Examine the Possible Association of Hepatic CYP3A Activity and the Susceptibility to Femur Head Necrosis
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 200
- 试验地点
- 1
研究概览
简要总结
The purpose of the present study was to examine the possible association of hepatic CYP3A activity and the susceptibility to femur head necrosis in patients treated with corticosteroids.
详细描述
Femur head necrosis is one of the major side effects of corticosteroid therapy. Since corticosteroids are metabolized by hepatic cytochrome P-450 (CYP) 3A, a low endogenous activity of this enzyme may contribute to the pathogenesis of ONFH. The purpose of the present study was to examine the possible association of hepatic CYP3A activity and the susceptibility to femur head necrosis in patients treated with corticosteroids.
研究设计
- 研究类型
- Observational
- 观察模型
- Defined Population
- 时间视角
- Other
入排标准
- 年龄范围
- 14 Years 至 70 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Clinical diagnosis of avascular necrosis of the femur
排除标准
- •Old age (> 70 years)
- •Severe hepatic or renal dysfunction
- •Heart disease
- •Current use of known CYP3A-inducing or -inhibiting drugs
- •Morbid obesity
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Studying the relationship between the CYP3A and CYP2D6 probe dextromethorphan and the pharmackinetics of tamoxifen.10006291breast cancerNL-OMON33769Erasmus MC, Universitair Medisch Centrum Rotterdam37
已完成
1 期
Effect of CYP3A Genetic Polymorphisms on the Pharmacokinetics of AtorvastatinCoronary Heart DiseaseNCT00973986Liuhuaqiao Hospital20
已完成
不适用
Alfentanil: Simultaneous Testing PilotEvaluate Two Paradigms for Simultaneous Assessment of Hepatic and Intestinal CYP3ANCT01008059Washington University School of Medicine6
已完成
1 期
A Study to Estimate the Effect of CYP3A4 Inhibitors (Itraconazole, Diltiazem or Verapamil) on the Pharmacokinetics of Single Dose PF- 00489791 in Healthy VolunteersHealthy VolunteersNCT02319148Pfizer22
已完成
1 期
Study To Assess The Impact Of Hepatic Impairment On The Safety, Tolerability And Pharmacokinetics Of Single-Dose 200 Mg Of PF-868554HEPATITIS C (HCV)NCT00651027Pfizer24